JP2018511609A5 - - Google Patents

Download PDF

Info

Publication number
JP2018511609A5
JP2018511609A5 JP2017551276A JP2017551276A JP2018511609A5 JP 2018511609 A5 JP2018511609 A5 JP 2018511609A5 JP 2017551276 A JP2017551276 A JP 2017551276A JP 2017551276 A JP2017551276 A JP 2017551276A JP 2018511609 A5 JP2018511609 A5 JP 2018511609A5
Authority
JP
Japan
Prior art keywords
antibody
binding fragment
antigen
administration
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017551276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511609A (ja
JP6944375B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/024624 external-priority patent/WO2016160756A2/en
Publication of JP2018511609A publication Critical patent/JP2018511609A/ja
Publication of JP2018511609A5 publication Critical patent/JP2018511609A5/ja
Application granted granted Critical
Publication of JP6944375B2 publication Critical patent/JP6944375B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017551276A 2015-03-31 2016-03-29 発作性夜間血色素尿症（ｐｎｈ）患者の亜集団の同定および処置 Active JP6944375B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562140711P 2015-03-31 2015-03-31
US62/140,711 2015-03-31
PCT/US2016/024624 WO2016160756A2 (en) 2015-03-31 2016-03-29 Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patents

Publications (3)

Publication Number Publication Date
JP2018511609A JP2018511609A (ja) 2018-04-26
JP2018511609A5 true JP2018511609A5 (https=) 2019-05-09
JP6944375B2 JP6944375B2 (ja) 2021-10-06

Family

ID=55702135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017551276A Active JP6944375B2 (ja) 2015-03-31 2016-03-29 発作性夜間血色素尿症（ｐｎｈ）患者の亜集団の同定および処置

Country Status (4)

Country Link
US (1) US20190135903A1 (https=)
EP (1) EP3277715A2 (https=)
JP (1) JP6944375B2 (https=)
WO (1) WO2016160756A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
JP7364221B2 (ja) * 2017-03-06 2023-10-18 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗ｃ５抗体およびその使用
DK3658184T5 (da) * 2017-07-27 2024-08-26 Alexion Pharma Inc Højkoncentrerede anti-c5-antistofformuleringer
CN118512588A (zh) 2017-10-26 2024-08-20 亚力兄制药公司 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用
CA3274059A1 (en) 2017-12-13 2026-03-02 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
EP3802593B1 (en) 2018-05-31 2024-09-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
EP3802603A1 (en) 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
US12312394B2 (en) 2018-06-28 2025-05-27 Alexion Pharmaceuticals, Inc. Methods of producing anti-C5 antibodies
JP7653909B2 (ja) 2018-09-06 2025-03-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒト化抗ｃ５抗体とその利用
EP3873602B1 (en) * 2018-10-30 2023-12-06 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20090220508A1 (en) * 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
IL288931B2 (en) * 2013-03-14 2025-05-01 Alnylam Pharmaceuticals Inc Compositions comprising a complementary portion of C5 IRNA and methods of using them
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics

Similar Documents

Publication Publication Date Title
JP2018511609A5 (https=)
US12029788B2 (en) Methods for increasing lean body mass with an exercise regimen and a GDF8 inhibitor that is an anti-GDF8 antibody
JP7744190B2 (ja) リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
JP2022141868A (ja) 心血管リスクを低減させる方法
AU2018306612B2 (en) High concentration anti-C5 antibody formulations
JP2023517236A5 (https=)
JP2012525128A5 (https=)
JP2022105625A5 (https=)
JP2010528047A5 (https=)
JP2013538796A5 (https=)
JP2011504872A5 (https=)
JP2017536414A5 (https=)
JP2018500014A5 (https=)
JP2021525718A5 (https=)
KR20210089214A (ko) 항-FcRn 항체를 이용한 그레이브스 안병증의 치료 방법
JP2016528247A5 (https=)
EA031436B1 (ru) Водная фармацевтическая композиция, содержащий ее предварительно заполненный шприц и применение композиции в лечении аутоиммунных заболеваний
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2022512632A5 (https=)
CA3181026A1 (en) Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
JP2023533030A5 (https=)
JP2019520316A5 (https=)
JP2018529661A5 (https=)
KR20230044312A (ko) 보체 매개된 질환을 갖는 대상체의 염증성 시토카인 및 피로
JP2019521156A5 (https=)